Piramal Pharma's Q1 FY 2026-27 Quarterly Results

Result Summary

• Piramal Pharma Ltd reported a 15.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 18.4%.
• Its expenses for the quarter were down by 8.0% QoQ and up 13.1% YoY.
• The net profit increased 686.7% QoQ and decreased 15.1% YoY.
• The earnings per share (EPS) of Piramal Pharma Ltd declined at 0.52 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Piramal Pharma Ltd is a prominent player in the pharmaceutical industry, offering a diverse range of products and services. The company is involved in the development, manufacturing, and commercialization of a wide array of pharmaceutical products, including active pharmaceutical ingredients (APIs), drug formulations, and consumer healthcare products. Piramal Pharma operates across multiple segments, catering to both domestic and international markets. The company is known for its focus on innovation and quality, striving to meet global healthcare needs. While specific recent developments were not provided, Piramal Pharma continues to be a significant entity within the pharmaceutical sector.

Revenue

In Q1FY27, Piramal Pharma Ltd reported a total income of ₹2359.33 crores. This represents a decrease of 15.7% compared to the previous quarter (Q4FY26), where the total income was ₹2797.83 crores. However, when compared year-over-year to Q1FY26, where the total income was ₹1992.11 crores, there was an increase of 18.4%. The decline in quarterly revenue may suggest various factors at play, while the yearly increase signifies growth over the previous year.

Profitability

Piramal Pharma Ltd's profitability in Q1FY27 saw a significant shift, with the company reporting a profit before tax of -₹27.02 crores. This reflects a substantial decline from the preceding quarter (Q4FY26), where the profit before tax stood at ₹29.43 crores, marking a QoQ change of -191.8%. Compared to the same quarter in the prior year (Q1FY26), where the profit before tax was -₹97.59 crores, the company shows a YoY improvement of 72.3%. The tax expenses for Q1FY27 were ₹61.93 crores, which increased by 19.5% from the previous quarter and by 2210.8% year-over-year. Consequently, the profit after tax for Q1FY27 was -₹69.39 crores, contrasting with -₹8.82 crores in Q4FY26 and -₹81.70 crores in Q1FY26. The earnings per share also reflected these changes, at -₹0.52 for Q1FY27, compared to -₹0.07 in Q4FY26 and -₹0.62 in Q1FY26.

Operating Metrics

The total expenses incurred by Piramal Pharma Ltd in Q1FY27 were ₹2386.35 crores, representing an 8.0% decrease from the previous quarter's expenses of ₹2592.63 crores. Year-over-year, there was a 13.1% increase in expenses compared to Q1FY26's figure of ₹2110.44 crores. These expenses include all operating costs, which have seen a reduction on a quarterly basis but an increase annually. The operating metrics reveal a dynamic financial environment, with fluctuating income and expenses impacting the overall financial standing of the company.